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Abstract
The mTOR inhibitor everolimus (RAD001, Afinitor) is an orally active anticancer agent. Everolimus demonstrates
growth-inhibitory activity against a broad range of tumor cell histotypes in vitro and has the capacity to retard tumor
growth in preclinical tumor models in vivo through mechanisms directed against both the tumor cell and the solid
tumor stroma components. These properties have rendered it to be a clinically active drug, with subsequent regis-
tration in renal cell carcinoma (Motzer et al. [2008]. Lancet 372, 449–456) as well as showing strong potential as a
combination partner (André F et al. [2008]. J Clin Oncol 26. Abstract 1003). Although everolimus has a high specificity
for itsmolecular target, the ubiquitous nature ofmTOR and themultifactorial influence that mTOR signaling has on cell
physiology have made studies difficult on the identification and validation of a biomarker set to predict and monitor
drug sensitivity for clinical use. In this review, a summary of the preclinical and clinical data relevant to biomarker
development for everolimus is presented, and the advantages and problems of current biomarkers are reviewed. In
addition, alternative approaches to biomarker development are proposed on the basis of examples of a combination of
markers and functional noninvasive imaging. In particular, we show how basal levels of pAKT and pS6 together could,
in principle, be used to stratify patients for likely response to an mTOR inhibitor.
Translational Oncology (2010) 3, 65–79
Introduction
Afinitor (generic name everolimus, also known as RAD001) is an
orally active derivative of rapamycin that inhibits the Ser/Thr kinase,
mTOR. This mTOR inhibitor (mTORi) was recently approved by
the Food and Drug Administration and European Medicines Agency
for treatment of renal cell carcinoma (RCC) after failure of vascular
endothelial growth factor receptor (VEGF-R)–targetted therapy in-
cluding the multikinase inhibitors sorafenib and sunitinib. Everolimus
is also currently in a number of phase 2/3 clinical trials in many dif-
ferent cancer indications for its utility alone and in combination with
other chemotherapeutics. Recently published studies have evaluated
treatment regimens of everolimus in the clinic and monitored the
activity of everolimus using various markers related to mTOR inhibi-
tion and cellular proliferation rates. Preclinical evaluation of these
biomarkers, and pharmacokinetic/pharmacodynamic (PK/PD) mod-
eling of preclinical in vivo studies, provided the basis for their clin-
ical application and successfully predicted clinically useful treatment
regimens for everolimus after the principle of determining optimal
biologic regimens. In this report, we briefly review the mTOR litera-
ture to date, with an emphasis on everolimus, and explore alterna-
tives to the further optimization of translational biomarkers that could
be applied.
Mechanism of Action
The target of the rapamycin class of agents is mTOR, a multifunctional
signal transducing protein, which obtains signals from many upstream
pathways and propagates the information through the regulation of
multiple downstream pathways [1]. Rapamycins function to block
mTOR activity by interacting with the immunophilin FKBP-12
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(Figure 1A), which forms an inhibitory complex that binds with high
affinity to mTOR. The signal transduction that occurs downstream
from mTOR is rapamycin-sensitive and occurs through an mTOR-
Raptor complex, known as TORC1. In addition, there is a TORC2
rapamycin-insensitive pathway when mTOR is complexed with Rictor
(Figure 1B), which is also known as PDK2. However, besides serving
a key role in normal cell physiology, mTOR has been implicated in
cancer [2,3], and consequently, inhibition of this target has received
considerable attention as an anticancer approach, leading to the clinical
development of rapamycin analogs (rapalogs) with improved druglike
properties such as everolimus [4,5].
The primary downstream targets of mTORC1 include eIF-4E–
binding protein (4E-BP1) and S6 kinase 1 (p70S6K1), i.e., S6K. On
mitogen-induced multisite phosphorylation, 4E-BP1 releases eIF-4E
allowing cap-dependent translation of several mRNA encoding critical
regulators of G1-phase progression. S6K functions in G1, through phos-
phorylation of the 40S ribosomal protein S6, to increase the translation
of mRNA that largely encode ribosomal proteins and other elements
of the translational machinery. Thus, through inhibition of mTOR
function, rapalogs block these essential translational events, resulting
in the inhibition of G1 progression (Figure 1B). Interestingly, inhibition
of mTOR by rapalogs seems to predominantly signal through S6K, re-
sulting in increased G1 block and decreased hypoxia-inducible factor
(HIF) translation rather than through c-myc [6]. Furthermore, mTOR
apparently resides in different subcellular locations and has several
macromolecular structure(s) due to differential binding/association
of other proteins. In congruence, some of the activities of mTOR seem
to vary with different cell types [2], and consequently, the exact activities
of rapalogs may also vary depending on the cell type. Rapalogs also
possess antiangiogenic/antivascular activities [7–9]. The exact mecha-
nism of action in endothelial cells, therefore, may be different than
that occurring in tumor cells: for example, in addition to suppressing
the effects of HIF-1 mediated endothelial cell proliferation, rapamycin
can block CD40-mediated VEGF release and endothelial cell prolifera-
tion [10].
Chemical Structure, Properties, and Metabolism of Everolimus
Everolimus is amacrolide lactone, and the structural formula is shown
in Figure 1C . Everolimus is a good substrate for the multidrug-resistant
pump P-gp. After incubating with liver microsomes in vitro [11], ever-
olimus is metabolized to more than 20 different metabolites, which is
almost exclusively owing to the activity of the P450 enzyme CYP3A4
[12]. A similar metabolite pattern was seen in animals and humans
after dosing with radioactive everolimus (unpublished observations).
In humans, 24 hours after an oral dose of 3 mg, 40% of everolimus
was unchanged; there were five major metabolites (each 4%-13%),
and the other minor metabolites comprised 18%. The major metabo-
lites showed little or no antiproliferative activity against activated lym-
phocytes or human tumor cells in vitro, with IC50 values more than
100-fold greater than everolimus (unpublished observations).
In experimental tumor models, everolimus is very well tolerated with
no obvious clinical signs of toxicity and normally leads to slight body
weight gains in comparison to vehicle-treated mice. The maximum tol-
erated dosage was not reached even when treating for up to 60 mg/kg
per day by oral gavage.
Figure 1.Mechanism of action and structure of everolimus. (A) Everolimus (yellow-red) binds to the FK506-binding protein-12 immunophilin,
FKBP-12 (white), and this complex interacts with the FRB domain (blue) of the large protein mTOR. (B) PI3K/AKT/mTOR pathway: the FKBP-
12-RAD001 complex inhibits mTORC1 function. 4E-BP1 indicates eIF-4E (eukaryotic initiation factor 4E) binding protein 1; HIF-1, hypoxia-
inducible factor 1 or 2; mTORC1/2, mammalian target of rapamycin complex 1 or 2; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase
and tensin homologue, dual-specificity lipid/protein phosphatase; S6K, 40S ribosomal S6 kinase; TSC1/2, tuberous sclerosis tumor suppres-
sor genes;VHL, vonHippel–Lindau protein. Tumor suppressors are in brown and underlined. (C)Molecular structure of everolimus (RAD001).
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In Vitro Preclinical Pharmacology of Everolimus as
a Single Agent
As a single agent, everolimus inhibits the in vitro growth of a wide variety
of mammalian tumor cell lines. As for rapamycin, the dose-response
curve for inhibition of proliferation is, for most cell lines, rather broad
(Figure 2), although there are exceptions. In general, 100%cell kill is not
seen, and the inflection point, which can be equivalent to the IC50, is
often broad. Consequently, the IC50 represents the concentration that
reduces cell proliferation (compared with control) by 50%, and if a 50%
reduction is not reached, then no IC50 can be measured. Using this
approach, everolimus produced a range of IC50 values that was inde-
pendent of histotype in the 48 different cell lines tested (Figure 3A).
A break point is apparent at ca. 100 nM, and indeed 71% (0.71
in Figure 3B) of the cell lines had an IC50 less than this (actually
≤65 nM) or 75% (IC50 actually ≤327 nM) using 350 nM as the cutoff
(blue dotted line). This arbitrary approach allowed a classification of
the cell lines into “sensitive” and “insensitive.”However, the PK of ever-
olimus in mice supports this cutoff because theCmax of the compound
is 107 nM in subcutaneously grown human tumor xenografts after a
single oral dose of 5 mg/kg (Figure 3C ), and everolimus is eliminated
frommouse plasma fairly rapidly with a half-life of ca. 5 hours. The PK
of everolimus in rats is rather different (Figure 3D), and there is a much
higher Cmax of 809 nM. Nevertheless, if the cell lines were grown in
nude rats, 25% would still be well below the IC50.
Consequently, on the basis of the PK of everolimus and individual
IC50 values, tumor cells have been described in general as either sensitive
or insensitive. However, isolated cells of both categories display inhibi-
tion of elements downstream from mTOR, notably reduction of pS6
and production of many bands of 4E-BP1 representing different stages
of hypophosphorylation [9]. This suggests that decreases in pS6 and/or
p4E-BP1 are markers of the target being hit by rapalogs but do not
necessarily predict response. Interestingly, for everolimus, continuous
exposure in vitro is not required for protracted activity against sensitive
cell lines. For example, treatment of the sensitive cell line human lung
A549 with a brief exposure of everolimus (20 nM for 30 minutes), fol-
lowed by washout into compound-free cell culture medium, resulted in
prolonged inactivation of the S6K [13]. Only 48 hours after removal of
everolimus from the A549 cell culture did S6K activity start to recover.
Furthermore, 96 to 120 hours after release, S6K1 activity did not reach
vehicle control–treated levels (0.14-0.5 of vehicle controls).
In Vivo Preclinical Pharmacology of Everolimus
as a Single Agent
PK of Everolimus in Tumor-Bearing Mice and Rats
There are key differences in the PK profile between mice and rats
[14]. In particular, there is greater partitioning of everolimus into eryth-
rocytes in rats (60%) compared with just 2% inmice but greater plasma
protein binding in mice (99.9%) compared with rats (92%). Further-
more, the plasma/blood half-life of everolimus is just 4 to 8 hours in
mice but 17 to 20 hours in rats (Figure 3, C and D). These PK differ-
ences have a major impact on the levels of unbound everolimus that
also is free in the plasma (not partitioned in red blood cells) of both rats
and mice. Consequently, applying the data in Figure 3, C andD, shows
that the free Cmax in both species is rather similar at ca. 1 nM with an
AUC0–24 hours of 5 to 8 nM. However, there are also important differ-
ences in the volume of distribution and tissue/tumor penetration.Mod-
eling of tumor and blood/plasma PK suggested that in mice, multiple
daily administrations result in a ∼2-fold increase in tumor levels of evero-
limus at steady state, whereas in rats, a ∼7.9-fold increase would occur.
In contrast, weekly high-dose regimens were predicted to not facilitate
tumor accumulation in either species. Interestingly, total tumor levels of
everolimus (Cmax and AUC) were four- to eight-fold greater in rats than
in mice, which could be partially influenced by the more than two-fold
greater plasma content and permeability of rat tumors compared with
mouse tumors [13].Overall, the PKof everolimus in rats wasmuchmore
similar to that in humans than mouse to humans. Finally, in rodents,
brain penetration of everolimus was poor but was dose-dependent and
showed overproportional uptake in rats, with a longer half-life com-
pared with the systemic circulation. These data imply that high in-
termittent doses may be more beneficial for brain tumors than lower
daily doses.
In Vivo Activity of Everolimus in
Tumor-Bearing Mice
In Vivo Target-Directed PD in Mice
As already described, everolimus has been demonstrated to inhibit
the phosphorylation and activity of the downstream mTOR-regulated
S6K in tumor cells, and this also has been shown in tumors and sur-
rogate tissues in both mice and rats [13]. Single administrations of
everolimus reduced the levels of S6 in both tumors and skin in a dose-
dependent manner, giving similar ED50 (effective dose reducing tumor
volume by 50%) values (0.8-1.0 mg/kg) but were slightly higher than
the ED50 of everolimus for antitumor effect against KB-31 tumors
(0.32 ± 0.04). Overall, the data suggested that antitumor effects seemed
to correlate with inactivation of the mTOR target S6K1 in treated tu-
mors at the higher doses but not necessarily at lower doses, suggesting
that a further antitumor mechanism may also exist such as antivascular
activity (see below). Strikingly, everolimus-induced effects on skin-
derived S6K activity were comparable with those obtained in tumor
material derived from the same mice, suggesting that skin sampling
in this context could provide a useful surrogate to tumor sampling. Fur-
thermore, assuming a linear response between the measured data, there
seemed to be an effect of concentration and time on the recovery rate of
S6K activity in pericytes peripheral blood mononucleocytes (PBMCs).
Evaluation of Everolimus in Mouse Models of Cancer
Everolimus is orally active in both mice and rats, producing an anti-
tumor effect that is characterized by dramatic reduction in tumor growth
Figure 2. In vitro activity of everolimus: examples of IC50 determi-
nation. Results show the dose-dependent inhibition of cell growth
by everolimus as a percentage of the control determined using
methylene blue staining after 96 hours of incubation in four different
human tumor cell lines, which can be regarded as sensitive (HCT-15,
A549) and insensitive (KB-31 and HCT-116).
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rates as opposed to producing tumor regressions, although regressions
can occur, for example, in subcutaneous A549 lung tumor xenografts,
a cell line classed as sensitive in vitro. On the basis of data generated in
Novartis Laboratories, Table 1 provides a detailed summary of the activ-
ity of everolimus against subcutaneous tumor xenografts in immuno-
deficient nude mice. Daily treatment (2.5-10 mg/kg) is well tolerated
and can produce antitumor effects similar to conventional cytotoxic
agents such as paclitaxel, 5-fluorouracil (5-FU), and doxorubicin but
without the associated body weight losses (Figure 4). Strikingly, activity
can also be observed in xenografts created from insensitive cell lines (i.e.,
HCT-116, KB-31, and KB-8511; Table 1). Indeed, when the IC50 val-
ues of 17 cell lines were compared with the maximal activity achievable
in vivo, there was no significant correlation (r = 0.25, P = .34 [9]), and
there was no correlation between in vitro IC50 and in vivo ED50 in seven
cell line/tumors [14]. These data, in addition to several different models
of angiogenesis both in vitro and in vivo, demonstrated a likely anti-
angiogenic/antivascular activity of everolimus, which would contribute
to its activity in vivo [9]. Note that the IC50 for everolimus was essen-
tially the same for both the low and high P-gp–expressing cell lines
KB-31 and KB-8511 (Table 1), suggesting that P-gp may play little role
in the sensitivity of cells to everolimus.
Consistent with the fact that the target needs to be consistently hit,
intermittent treatment with everolimus of mice bearing human colon
HCT-116 tumors reduced effectiveness. Furthermore, on cessation of
treatment, tumors quickly regained growth rates similar to those of the
vehicle control (Figure 4, C and D).
In general, similar observations have been described in the literature
for everolimus. Thus, although regression from monotherapy is seldom
seen, strong growth inhibition was observed in models of ovarian cancer
[7,15], colon cancer [8,16], prostate cancer with bone metastases [17],
leiomyosarcoma [18], gastrointestinal stromal tumors [19], endometrial
cancer [20], breast cancer [21], lymphoma [22], leukemia [23], and
thyroid cancer [24]. Activity normally matched that of conventional
agents and was increased in combination with cytotoxics such as cis-
platin [7,15] or paclitaxel [17] but also with other targeted agents such
as gefitinib [16], imatinib [19], and zoledronate [17] and also ionizing
Figure 3. In vitro activity of everolimus against mammalian cell lines and PK in mice and rats. Everolimus in vitro activity in 48 different cell
lines assessed by IC50 values in ascending values (A) and ranked (B), showing cutoffs at 100 nM (red) or 350 nM (blue). Everolimus (RAD001)
was administered once at 5 mg/kg per os (p.o.) to (C) female BALB/c athymic nudemice bearing s.c. KB-31 tumors or (D) Lewis rats bearing
s.c. CA20498 tumors. Plasma/blood, tumors, and tissues were obtained at various time points after administration, and everolimus levels
were determined using high-performance liquid chromatography/mass spectrometry. Data are expressed asmean±SEM, n=4. Horizontal
lines represent the in vitro IC50 values shown in panels A and B, and the IC50 values for endothelial cells are from Lane et al. [9].
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radiation [8]. These preclinical observations are now being verified in
the clinic, for example, in the combination of everolimus with trastu-
zumab and paclitaxel in breast cancer [25].
In VivoActivity of Everolimus in Tumor-Bearing Rats
Everolimus has been extensively characterized with respect to dose
and scheduling using a syngeneic pancreatic tumor, CA20498, grown
subcutaneously in Lewis rats. The everolimus-dependent reduction
in S6 levels in rat CA20498 tumors, skin, and peripheral circulating
leukocytes was extensively studied [13] and modeled [26], based in part
on a previously developed PK model to predict and interpret clinical
trial data.
In the rat CA20498 model, daily treatment with everolimus (0.5 or
2.5mg/kg) dose-dependently inhibited growth, and intermittent dosing
using a higher dose of 5 mg/kg (once or twice per week) also showed
similar antitumor efficacy [13]. Inhibition by everolimus was character-
ized by sustained suppression rather than regression and was not associ-
ated with any body weight loss.
A single 5-mg/kg dose of everolimus (optimal for antitumor efficacy)
caused a dramatic reduction in S6 phosphorylation after 24 hours. In
contrast, a similar reduction was not observed in skin and PBMC ex-
tracts because these tissues exhibited no detectable S6 phosphorylation
at baseline, which may reflect the relatively low proliferative index of
these tissues compared with the highly proliferative CA20498 tumors.
In the tumors, significant inhibition of S6K1 activity was maintained
for up to 48 hours after everolimus treatment. At this time, S6K1 activ-
ity started to recover, but levels were still reduced compared with vehicle
controls at 72 hours (Figure 5). In comparison, S6K1 derived from skin
samples taken from the same rats remained significantly inhibited for
up to 72 hours. These data indicate that everolimus results in prolonged
inhibition of S6K1 in tumors and skin derived from tumor-bearing
rats, providing mechanistic support for the observed antitumor potency
of intermittent dosing schedules used in this rat model and suggesting
the potential of skin sampling as a source of material for biomarker eval-
uation in the clinic.
A similar but stronger reduction in S6K1 was seen in PBMCs iso-
lated 2 and 12 hours after administration, which was maintained for
up to 72 hours (Figure 5). Furthermore, an experiment investigating
the duration of effect of a single suboptimal (0.5 mg/kg) versus an opti-
mal (5 mg/kg) antitumor dose of everolimus indicated that the time
required for the recovery of S6K1 was dose-dependent. Thus, only
efficacious doses of everolimus result in sustained, significant S6K1 in-
activation for up to 7 days after administration (Figure 5D). These data
suggested a correlation between prolonged S6K1 inactivation inPBMCs
and optimal everolimus doses, eliciting significant antitumor responses
with intermittent (weekly) treatment schedules; a hypothesis confirmed
by amore detailed analysis presented byBoulay et al. [13]. Hence, blood
sampling could provide a source of material for biomarker evaluation
in the clinic.
Rapamycin is known to promote 4E-BP1 dephosphorylation, result-
ing in the repressive association of 4E-BP1 with the eIF-4E translational
activator [27]. Everolimus in vitro also promotes 4E-BP1 dephosphory-
lation in a number of cell lines, and consequently, a similar analysis to
that described above for S6K1 was performed. In all tissues, reductions
in threonine-70 4E-BP1 phosphorylation were observed after evero-
limus treatment, and this correlated with changes in the mobility of
the 4E-BP1 protein (particularly striking in PBMCs) and a trend for
increased association with eIF-4E. These data demonstrated activation
of 4E-BP1 as a translational repressor in tissue derived from everolimus-
treated tumor-bearing animals (unpublished observations).
Development of a PK/PD Model Using S6K Activity
in PBMC as a Biomarker for Everolimus
Detection of S6K1 Activity in Human PBMCs
To assess the potential of usingmTOR effectors as biomarkers to eval-
uate everolimus dosing schedules, basal S6K1 activity was measured in
Table 1. Anticancer Activity of Everolimus as a Single Agent In Vitro and in Athymic Nude Mice In Vivo.
In Vitro In Vivo
Tumor Origin Cell Line IC50 (nM) Optimal Treatment Regimen Tumor Response Host Response
T/C % Body Weight Change (Controls)
Sensitive in vitro Lung A549 2.4* Everolimus: 2.5 mg/kg per day −0.41† 1 ± 1 (6 ± 2†)
Doxorubicin: 9 mg/kg i.v., once every 7 days 0.49 −18 ± 1†
NCI-H520 42.6* Everolimus: 5 mg/kg per day 0.14† 4 ± 1 (6 ± 2)
Cisplatin: 5 mg/kg i.v., once every 7 days 0.34† −6 ± 2†
NCI-H596 5 ± 2 Everolimus: 5 mg/kg per day 0.18† 10 ± 1† (9 ± 1†)
Paclitaxel: 15 mg/kg i.v., three times per week −0.33† −32
Melanoma B16/BL6* 0.7 ± 0.2 Everolimus: 5 mg/kg per day 0.24† 9 ± 1† (−0.3 ± 3)
Insensitive in vitro Colon HCT-116 4125 ± 1853 Everolimus: 5 mg/kg per day 0.50 −6 ± 3 (7 ± 5)
5-FU: 75 mg/kg i.v., once every 7 days 0.30† −13 ± 4
Epidermoid KB-31 1778 ± 800 Everolimus: 2.5 mg/kg per day 0.26† 6 ± 1† (5 ± 2†)
Doxorubicin: 9 mg/kg i.v., once every 7 days 0.30† −8 ± 2†
KB-8511 1489 ± 806 Everolimus: 5 mg/kg per day 0.17† 2 ± 1 (6 ± 3†)
Paclitaxel: 15 mg/kg i.v., three times per week 0.71 −2 ± 5
In vitro IC50 determinations. Each cell line was added to 96-well plates (1000-3000 cells/well in 100 μl of medium) and incubated for 24 hours. Subsequently, everolimus was added in a two-fold dilution
series, and the cells were reincubated for 3 days. Methylene blue staining was performed on day 4, and the amount of bound dye (proportional to the number of surviving cells that bind the dye) was
measured. IC50 values were determined using the SoftmaxPro program. In vivo evaluations used s.c. xenografts of human tumor cells in nude mice and also the murine B16/BL6 cell line growing
intradermally in the ear as a syngeneic orthotopic model.
T/C: mean increase of tumor volumes of treated animals divided by the mean increase of tumor volumes of control animals.
Percent body weight change is (g body weight at end of experiment − g body weight at beginning / g body weight at beginning) expressed as a percentage.
i.v. indicates intravenous.
*Mean of duplicate determinations; all others mean ± SEM of n = 4-7 determinations.
†P < .05 versus controls, but for tumor volume changes, the statistical significance used Δ tumor volumes (tumor volume at end of experiment − tumor volume at beginning).
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human PBMC extracts obtained from healthy volunteers [13]. Using
EDTA as an anticoagulant, a coefficient of variation (for PBMC prepa-
ration and kinase assay) of just 10% was obtained, indicating good re-
producibility of preparation. Treatment of healthy volunteer blood with
2 nM everolimus for 30 minutes diminished S6K1 activity compared
with vehicle controls (44% and 63% inhibition in donors 1 and 2, re-
spectively). Furthermore, increasing everolimus concentrations led to
almost complete inactivation of S6K1 (≥95% inhibition with ≥20 nM
everolimus). In contrast, no 4E-BP1 phosphorylation could be detected
in human PBMCs, and because 4E-BP1 is not an enzyme, a quantitative
assay is not readily available. Consequently, unlike S6K1, 4E-BP1 pro-
tein may not be applicable as a biomarker for monitoring everolimus-
specific effects in human PBMCs.
Everolimus is a targeted, highly specific agent with an IC50 for binding
to isolated FKBP-12, or FKBP-12 complexed to mTOR of 5 to 6 nM,
and no significant activity against other protein kinases (D. Fabbro, PhD,
T. Meyer, PhD, and H.A. Lane, PhD, unpublished observations). Thus,
this affords the opportunity to administer a dosage regimen that pro-
vides a sufficient drug level to inhibit a biologic end point, providing
an optimal biologic dose (OBD) and, consequently, avoiding the ad-
verse events likely to be associated with dosing dictated by the maxi-
mum tolerated dose. With the information described above, a PK/PD
Figure 4. Efficacy and tolerability of everolimus in mice bearing s.c. human tumor xenografts. (A and B) When tumors reached 100 mm3,
everolimus was administered daily at 0.1, 0.5, or 2.5 mg/kg p.o. to mice bearing NCI-H596 human lung tumor xenografts. Alternatively, mice
received5mg/kg cisplatin intravenously onceperweek. Results show themean±SEM (n=8) for tumor volume (A) andbodyweight (B).Only
the2.5-mg/kgper day regimenof everolimusproduceda statistically significant reduction in tumor volume (Dunnett’s test vs vehicle controls).
(C and D)When HCT-116 tumors reached 100mm3, everolimus was administered daily at 2.5 or 5 mg/kg from day 7 to day 25 (C) or (D) until
day 35 in comparison to only day 7 to day 25. Alternatively, mice received 75mg/kg 5-FU once per week. Results show themean± SEM (n=
7) for tumor volume, where *P < .05 versus controls by Dunnett’s one-way ANOVA.
70 Biomarker Development for Everolimus O'Reilly and McSheehy Translational Oncology Vol. 3, No. 2, 2010
model, which could be used to guide clinical administration regimens
to reduce the time for initial clinical trials by aiming for an OBD and
regimen, was sought [26]. PK/PD models associate dose-concentration
relationships (PK) with concentration-effect (PD) to provide a predic-
tive model for the time course of drug effects, which can be used to
optimize clinical regimens. The key assumption of this work is that a
clinically effective everolimus administration regimen should provide a
degree and duration of S6K1 inhibition in PBMC and tumor tissues
that has been associatedwith an antitumor effect, as was observed in rats.
Rat data were also used because everolimus PK in this species resembles
that of humans much more than that of mice [14].
Modeling of the rat data (blood and tumor PK, S6K inhibition in
tumor, and PBMC) indicated that the everolimus dosage regimen had
a greater influence on tumor S6K activity than on PBMC S6K activity,
with daily everolimus dosing giving more complete and sustained
inhibition of S6K than once-weekly administration [26]. Additional
modeling of rat (and mouse) PK also suggested that significant tumor
accumulation of everolimus of approximately eight-fold in rats and two-
fold inmice would occur with daily dosing but none with weekly dosing
[14]. Extending the model to include data from cancer patients [28]
indicated that, other than correcting for the differences in PK properties
of everolimus between humans and rats, the model also accurately fits
Figure 5. Duration (A, B, C) and recovery (D) of the effects of everolimus on S6K1 activity in CA20498 tumors, rat skin, and PBMCs after a
single dose (5 mg/kg). Lewis rats bearing CA20498 tumors were treated with a single dose of 5 mg/kg everolimus or vehicle. At the times
indicated, tumor (A) and skin (B) extracts from three rats were prepared separately, and PBMC (C) extracts were prepared from pooled blood
samples. p70S6K1 activity was measured using 40S ribosomal subunits as an in vitro substrate. In each case, autoradiographs of [32P]phos-
phate incorporation into S6 protein are shown. Graphs represent PhosphorImager quantification of the autoradiographs, where *P < .05
versus untreated controls (Dunnett’s test); from Boulay et al. [13]. (D) S6 kinase activity was determined in circulating PMBCs from rats
treated with 0.5, 1, 2, and 5 mg/kg everolimus once per day. The PK profiles were based on a single administration of everolimus at
5 mg/kg, and the everolimus concentrations obtained with doses were estimated assuming a linear PK profile. Inspection of the data sug-
gests that 0.03 ng/ml blood seems to be a minimal value below which recovery of S6K activity begins. Back extrapolation of the S6 phos-
phorylation curves suggests that, by the first measured time point, the recovery process of S6K has already begun with the 0.5 mg/kg dose,
with the estimated rate of recovery being 0.425, and the estimated blood everolimus (RAD001) level was approximately 0.05 ng/ml. How-
ever, considering the other dose groups, the recovery of S6K activity seems to occur when the drug level is approximately 0.03 ng/ml. The
recovery after 1, 2, or 5 mg/kg everolimus began at 24, 72, and approximately 125 hours after everolimus administration, respectively. The
S6K recovery rate was 0.408, 0.284, and 0.244 for 1, 2, and 5 mg/kg everolimus. The time where blood levels drop below 0.03 ng/kg evero-
limus was correlated to the S6K recovery rate (setting the initiation of recovery at 12 hours for the 0.5-mg/kg dose) (r=−0.968, P= .0316).
The total amount of S6K inhibition (AUC) was correlated to the estimated everolimus AUC at each dose (r = 0.96, P = .038) and the evero-
limus AUC was also correlated to the rate of S6K recovery (r = 0.95, P = .046).
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the inhibition of S6K1 in the PBMC of cancer patients. This provided
evidence that there is little difference between tumor-bearing rats and
cancer patients regarding the concentration effect of everolimus and
its PD effect on signal transduction proteins. However, it is important
to note that this may not be the case for brain tumors, where weekly
dosing may be preferred, because everolimus only significantly accumu-
lated in rat brain at higher doses [14].
PD Studies with the Rapalog Temsirolimus
A similar set of studies in PBMC was performed with temsirolimus
(i.e., CCI-779) [29]. These studies demonstrated a linear dose response
for rapamycin-dependent inhibition of S6K in lymphoid cells and re-
duced S6K activity in the PBMCs and subcutaneous (s.c.) tumors of
treated mice. Furthermore, in PBMCs from human volunteers, S6K
activity was stable for 8 days incubated ex vivo, although substantial vari-
ation in the levels occurred. Lastly, in PBMCs taken from a small group
of advanced renal cancer patients treated with temsirolimus, there was
a strong impairment of PMBC S6K activity that was protracted and
showed a linear relationship between the extent of decrease in S6K ac-
tivity and time to treatment failure. Overall, these studies support the
use of PBMC S6K activity as a marker for the effects of rapalog-based
therapy for cancer.
Clinical Pharmacology and Efficacy of Everolimus
as a Single Agent
The PK/PD model described [26] was used and further refined in a
phase 1 study [28], with the PD marker being PBMC S6K1 activities.
The study continued with a safety evaluation of everolimus, with a sec-
ondary evaluation being efficacy. The PK of everolimus in cancer
patients (n = 4-6 per dose) with a once-weekly administration demon-
strated minimal plasma accumulation, and steady state was obtained af-
ter two treatments. TheCmax at steady state increased in a dose-dependent
manner at 5, 10, and 20 mg and was less than dose-proportional at
30, 50, and 70 mg; AUC, however, remained dose-proportional. The
elimination half-life was approximately 30 hours at all doses.
The PBMC sampling strategy used several samples before treatment
to establish a baseline of S6K1 activity. An example of the data obtained
from single doses of everolimus is presented in Figure 6B, which shows
that the interpatient and intrapatient PBMC S6K1 levels varied con-
siderably. However, the levels of PBMC S6K1 were uniformly dramati-
cally reduced during the time of high blood levels of everolimus and
increased again when everolimus levels dropped below ca. 2 ng/ml
(i.e., 2 nM; Figure 6A). This recovery of S6K1 was apparently partially
dose-dependent (Figure 6C). Continuous suppression of pS6 levels in
PBMC was achieved with doses greater than 20 mg (once weekly) and
at both 5- and 10-mg doses when administered once daily. These clini-
cal data are in congruence with the predictions from the PK/PDmodel.
In general, the safety profile in this phase 1 trial was considered good
(92 patients), with only two patients showing dose-limiting tolerability
issues. Thus, the maximum tolerated dose was not reached, although
almost every patient had some adverse event related to drug dosing.
Furthermore, partial responses were seen in four patients, and 12 pa-
tients were progression-free for greater than 6 months, including 5 of
10 patients with RCCs. Overall, it was concluded that on the basis of
Figure 6. Data in panels (A) and (B) are from the patient group dosed with 5 mg of everolimus as described by O’Donnell et al. [28]. (A)
Everolimus blood PK (open symbols) with the PD readout of S6K activity (closed symbols) in circulating PBMCs from treated patients. (B)
Time-dependent PBMC S6K levels in four individual patients. (C) Recovery of S6K acitivity in PBMC from patients receiving various doses (5-
30 mg) of everolimus [28].
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these PK and PD readouts, theminimumdoses of 5mg/d or 20mg/week
should be used in further clinical development [28].
A concomitant phase 1 study also studied dose and schedule with PK
and more extensive PD readouts [30]. They determined pretreatment
and on-treatment steady-state tumor and skin biopsies for a variety of
markers (both total and phosphorylated state) using immunohisto-
chemistry (IHC) for S6K1 elF-4E, 4E-BP1, p4E-BP1-Thr70, eIF-4G,
AKT, and Ki-67 expression. During the first 4 weeks of treatment, irre-
spective of the administration regimen, plasma trough levels of evero-
limus were determined once per week before dosing.
Trough levels of everolimus were, respectively, 8.5 and 17 ng/ml
for 5 and 10 mg administered daily, whereas weekly administration of
20, 50, or 70 mg produced trough levels of 0.1, 1.0, and 4.2 ng/ml,
respectively. There was almost complete and sustained inhibition of
pS6 and p-eIF-4G in both tumor and skin at the trough concentration
of 10 mg daily and more than 50 mg weekly. Strangely, this did not
occur with the 5-mg daily dosage, although trough levels were higher
than the 50- and 70-mg weekly regimens. Significant inverse correla-
tions occurred between the daily dose of everolimus and p-eIF-4G and
pS6 levels, but sustained reduction occurred only at 50- and 70-mg
doses. Although not observed in all patients, everolimus caused dra-
matic reductions in skin p-4E-BP1, but the effect on tumor was less
profound; however, when inhibition occurred, it was sustained. There
was an increase in pAKT (Ser473) in tumor and skin in 50% of the pa-
tients, and in some cases, this was sustained. Cellular proliferation, as
indicated by Ki-67 nuclear staining, was variably reduced in both tumor
and skin by everolimus treatment. An analysis linking trough levels of
everolimus with the PD readouts indicated a significant correlation be-
tween PK and p-4E-BP1, a trend for a correlationwith p-eIF-4G, but no
correlation between pAKTand trough levels; the near-complete reduc-
tion of pS6 at all doses prohibited any correlation analyses. Importantly,
there was no change in the total levels of S6, 4E-BP1, eIF-4G, or AKT,
suggesting that the observed changes in phosphorylated levels of these
proteins were due to the inhibition ofmTOR-dependent signal transduc-
tion and protein activation as opposed to the changes in protein levels.
Comparing the two schedules, mTOR pathway inhibition was more
profound (and maintained) with the daily schedule. Although PBMC
samples were not analyzed in this clinical study [30], the PD effects
of everolimus on pS6 levels in patients’ tumor and skin paralleled the
observations made in CA20498 pancreatic tumor-bearing rats [13];
this effect was also observed using KB-31 tumor-bearing nude mice
(A. Boulay, PhD, T. O’Reilly, PhD, and H.A. Lane, PhD, unpublished
observations). Thus, in congruence with the PK/PDmodeling of animal
data [26], the clinical data indicated a difference in the PD effects caused
by everolimus depending on the regimen, with more sustained inhibi-
tion of mTOR signaling components with daily or high-dose once-
weekly dosing, whereas lower doses given once weekly could not achieve
durable inhibition of downstream target effectors.
As in the clinical study of O’Donnell, all patients in the Tabernero
study showed some adverse event, but only 5 of 55 patients demon-
strated dose-limiting toxicities. Four patients demonstrated clinical
benefit (all receiving weekly dosages of 20-70 mg weekly), including
one partial response in a heavily pretreated patient with metastatic
colorectal cancer treated who received 20mg of everolimus once weekly.
Three patients showed disease stabilization for more than 5 months, in-
cluding one with advanced renal cell cancer and two with advanced
breast cancer [30].
These initial clinical responses in the phase 1 studies described, plus
impressive response rates in another phase 2 study for RCConly recently
reported [31], encouraged a phase 3 registration trial in RCC, known as
RECORD-1 [32]. An update of this trial showed an impressive exten-
sion of progression-free survival from 1.9 months in the placebo arm to
4.9 to 5.5months in the everolimus arm, despite a relatively low (partial)
response rate of just 2% [33]. Such data emphasize that, for a cytostatic
agent such as everolimus, clinical benefit may not necessarily be detected
using RECIST criteria but rather may require suitable biomarkers for
early detection of response.
Limitations of Currently Used Biomarkers
for Rapalogs
Biomarkers are objectively determined indicators of normal or patho-
logic biologic processes or a response to a pharmacological agent [34].
They are categorized as markers of 1) natural history (type 0), indicating
disease progression or resolution, independent of any particular therapy,
and are often used for patient stratification in clinical trials; 2) drug ac-
tivity (type 1), indicating response to drug therapy that can be used in
optimizing therapeutic intervention; or 3) surrogate (type 2), which is
intended to substitute for clinical end points.
S6K activity is elevated in many cancer cells, but this seems to be a
consequence of alterations at other points in the PI3K/AKT/mTOR
pathway, as opposed to being tumorigenic in itself. Furthermore, there
is little information that would securely suggest that reduction of S6K
activity would be directly indicative of a clinical outcome. Accordingly,
S6K activity used as a biomarker would be classified at present as a type
1 marker; however, it cannot be considered a specific marker for mTOR
inhibition or for the detection of the “sensitivity” toward rapamycin
derivatives because both “sensitive” and “insensitive” cells demonstrated
reduction of S6K activity, as described above [9]. However, S6K may
indeed be a possible marker for clinical outcome because overexpression
of S6K has been shown to be related to increased in vitro sensitivity
toward rapamycins in a series of breast cancer cell lines [35,36] and
because higher levels of S6K expression are associated with increased
local recurrence in breast cancer and lower levels are associated with re-
duced disease-free interval in both breast cancer [37] and renal cancer
patients [29].
Although clearly proven useful in determining optimal monotherapy
regimens for clinical evaluation of everolimus, use of S6K1 activity as a
type 1 biomarker will be difficult in the situations in combination with
other anticancer agents. This is because cytotoxic agents can modulate
components of the mTOR signaling pathway, e.g., etoposide, mitomy-
cin C, and cisplatin all reduce the activity of S6K1, with concomitant
reduction in the phosphorylation status [38]. Reduction of the phos-
phorylation of 4E-BP1 also occurred and increased its binding to
eIF-4E, which would prevent the binding of eIF-4E to the 5′-cap region
of mRNA to allow translation. Conversely, paclitaxel causes the phos-
phorylation of S6K at Thr421 and Ser424 in breast and ovarian cell lines
[39]. Furthermore, hypophosphorylated S6 protein seems to be a me-
diator of TRAIL-associated apoptosis induction, which occurs with a
variety of agents including tumor necrosis factor, cycloheximide, etopo-
side, doxorubicin, tunicamycin, and staurosporine [40]. Consequently,
the use of these markers as indicators of the activity of rapalogs when
used in combination with cytotoxic agents would be complicated.
Therefore, unless new markers of sensitivity to the combination partner
can be developed, use of “target-independent” tumor response measure-
ment methods (e.g., noninvasive imaging) may be required (see below).
Alternatively, these markers could be used as type 0 biomarkers.
Thus, basal levels of markers of mTOR pathway could, however, still
be useful in determining the potential sensitivity of the tumor, especially
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if several different markers are combined. A recent report studying
13 different human tumor cell lines showed a significant correlation be-
tween basal levels of pAKT (Ser473) and sensitivity to everolimus asmea-
sured by IC50 values (r = 0.73) and similar levels of correlation between
pGSK3 (Ser9) or pTSC2 (Thr1462) and IC50 [41]. PTEN status was
not examined in this report, whose loss of function has been thought
to render cells more dependent on the mTOR signaling cascade and,
accordingly, more sensitive to mTOR inhibition. However, our obser-
vations suggest that PTEN status does not predict well the in vitro sen-
sitivity to everolimus with the exception of glioblastomamultiforme cell
lines (Figure 7). However, PTEN status was used in clinical trials of the
rapalog temsirolimus. Glioma andmelanoma are often PTEN-mutated,
but clinical trials of temsirolimus showed a low activity [42]. In contrast,
endometrial cancer (also often PTEN-mutated) patients demonstrated a
much better outcome when treated with temsirolimus. Although many
explanations could be offered, one proposal [42] is that the time of
PTEN mutation (late in melanoma and glioma; early in endometrial)
may dictate sensitivity to the inhibition ofmTORC1-independent path-
ways by rapalogs.
Finally, other potential biomarkers should also be considered as
potential stratifiers that are not strictly part of the PI3K/AKT/mTOR
pathway. For example, it was reported that loss of the tumor-suppressor
protein merlin and activation of mTORC1 are correlated in mesotheli-
oma and thatmerlin-negative lines are sensitive to the growth-inhibitory
effect of rapamycin, suggesting that loss of merlin may be a marker for
rapalog sensitivity in mesothelioma [43]. Also, those functions further
downstream of control of protein translation such as the effectors them-
selves such as HIF-1 and the many proteins that this transcription factor
regulates could also be stratifiers. Thus, rates of glycolysis and the degree
of vascularization maybe factors governing overall response to rapalogs,
although this has not yet been reported (also discussed below).
Combinations of Biomarkers
Single markers for stratification of the population, i.e., preselection of
the patients most likely to respond to chemotherapy are ideal but may
not suffice, and thus, the use of combinations of biomarkers may be
more appropriate. It has long been known that use of several markers
increases sensitivity and specificity of the prediction of therapeutic out-
come [44]. Using a total of 7 markers (6 in urine and 1 in plasma), both
as absolute values and as ratios, stepwise multiple regression techniques
demonstrated that a maximal of 15 markers (measured before and after
treatment and marker ratios) was required to obtain a maximal predic-
tive power of therapy for breast carcinoma patients; a 2.4-fold improve-
ment over the best single marker.
As an example of what might be achieved in the clinic using a com-
bination of biomarkers, we have applied a number of different statistical
approaches to a data set of 21 cell lines of diverse tumor origins with 1)
known sensitivity to everolimus (IC50) and 2) quantified levels (Western
blot with quantitation of light-emitting paper-bound immune com-
plexes) of several of the members of the AKT/mTOR pathway (total
S6 levels, p235-S6, p240-S6, pEIF4, Rictor, Raptor, total AKT, and
pAKT). In addition, the ratios of pS6/total S6, pAKT/AKT, and Rictor/
Raptor were determined (M.Klopfenstein, BSc,M. Breuleux, PhD, and
H.A. Lane, PhD, unpublished observations).
Univariate correlation analyses (Table 2) demonstrated significant
correlations between sensitivity to everolimus with the markers total
S6, p235-S6, total AKT, and pAKT by applying the Spearman rank cor-
relation test. Note that different answers were obtained depending on
whether IC50, log IC50, or rank IC50 were used, which seemed to be
due to the lack of normal distribution and the extent of kurtosis. In
the case of p235-S6/total S6, combining twomarkers as a ratio dramati-
cally improved both the correlation coefficient and the statistical signifi-
cance compared with use of a single marker. Perhaps interestingly, use of
the pAKT/total AKTratio was uncorrelated to everolimus sensitivity.
Thesemarkers were then used individually in linear regressionmodels
(Table 3). All models passed goodness-of-fit tests but varied dramatically
in their regression parameters, with p235-S6/total S6 providing the best
fit (r = 0.77), followed by pAKT (r = 0.69), p235-S6 (r = 0.51), total S6
(r = 0.48), and total AKT (r = 0.45). All of the measured data and their
ratios were then combined in multiple regression to search for an im-
proved predictive ability. Use of backward stepwise regression eliminated
two of the eight measured markers, and their ratios on the basis of their
lack of significance contribute to a regression function predicting rank
IC50. The regression yielded a highly significant fit (r = 0.98, ANOVA
P < .0001, each parameter fit P < .04; see Table 3). These data demon-
strate that the use of multiple biomarkers can lead to dramatic improve-
ment in predicting tumor cell sensitivity to everolimus. However, the
Figure 7. Role of PTEN in sensitivity of tumor cell lines in vitro to
everolimus. Results show the individual IC50 values for different
human tumor cell lines defined as glioblastoma multiforme (GBM)
or not, according to presence of PTEN mutation (P values from a
2-tailed t test).
Table 2. Univariate Correlation of Key mTOR Pathway Components and Sensitivity to Everolimus
On the Basis of Rank IC50.
Spearman Rank Correlation Coefficient
r P
pS6 240/244 0.06 0.80
pS6 235/236 0.53 0.01
Total S6 −0.51 0.02
pEIF4 −0.06 0.80
Raptor −0.01 0.98
Rictor −0.16 0.50
Total AKT 0.37 0.10
pAKT 473 0.66 0.001
235/total S6 0.76 <0.0001
240/total S6 0.30 0.18
235 + 240/total S6 0.52 0.01
Raptor/Rictor 0.19 0.40
pAKT/total AKT 0.41 0.07
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cost and time required to measure all of the parameters maybe prohibi-
tive.Use of just the ratio of p235-S6/total-S6 and pAKT (the two factors
correlating best with rank IC50) still provided a significant fit (r = 0.79,
ANOVA P = .0001), with the p235-S6/total-S6 ratio alone provid-
ing the major contribution (P = .0113) and pAKT providing much
less (P = .14).
In clinical decision making, discreet criteria (e.g., high vs low) are
preferable than continuous data, and an attempt was made to “convert”
the continuous data of the present data set. Recursive partitioning is a
technique that finds partitions of factors within a data set grouped by a
particular response [45]. Use of recursive partitioning to select which
markers best separated the cell lines when grouped according to rank
IC50 indicated that pAKT and the ratio p235-S6/total S6 significantly
segregated the 21 cell lines, with no other markers being identified
(Figure 8). Recursive partitioning suffers from being sensitive to changes
in the database, and particularly in the present case, a large database
is required for obtaining accurate results [45,46]. Therefore, the re-
sults obtained with the present database must be considered preliminary
in nature.
On the basis of this partitioning analysis, the cell lines were ranked
according to expression levels of pAKTand p235-S6/total S6 and were
plotted (Figure 9). Midpoints of the ranks were used to segregate the
lines into four categories on the basis of expression levels of the two
markers (Figure 9B). Finally, comparing the in vitro IC50 “cutoff” of
100 nM, which seems to segregate the cell lines into sensitive and in-
sensitive groups (see above), largely matched the categories of marker
expression level, with a high level expression of both pAKTand p235-
S6/total S6 representing the most sensitive tumor cell line phenotype
(Figure 9B). However, Figure 9C demonstrates that these categories
indeed overlap with respect to everolimus sensitivity, with only the high
pAKTand high p235-S6/total S6 and low pAKTand low p235-S6/total
S6 categories being statistically different. The use of other “cutoff levels”
for everolimus sensitivity, namely 20 and 4 nM (the approximate Cmax
and Cmin, respectively, on the basis of the administration of 10 mg to
cancer patients [28]) accordingly gave slightly different results. Lastly,
nominal logistic regression was performed using everolimus sensitivity
as the outcome categories (sensitive [S] or insensitive [IS]) and pAKT
and p235-S6/total S6 expression as the regressor categories (high pAKT
and high p235-S6/total S6, high pAKTand low p235-S6/total S6, low
pAKTand high p235-S6/total S6, and low pAKTand low p235-S6/total
S6). The models compared sensitivity criteria of IC50 < 100 nM (an
apparently naturally occurring breakpoint) and IC50 < 4 nM (the Cmin
unbound levels at steady state after 10-mg dosing [28]. With the
100-nM breakpoint, 13 cell lines were considered sensitive and 8 were
insensitive. The regression produced an adequate fit (r2 = 0.46, χ 2 P =
.025, with Wald test for goodness-of-fit passed), providing the resulting
receiver operating characteristic (ROC) curve (Figure 10A). The AUC
of this curve (0.88) suggests that the use of these two parameters pro-
vides a good indicator of everolimus sensitivity [47]. Using the categories
high pAKT and high p235-S6/total S6 (a predictor of sensitivity) and
low pAKT and low p235-S6/total S6 (a predictor of insensitivity), the
sensitivity is 73% and the specificity is 100%.With IC50 < 4 nM as the
sensitivity cutoff, 10 cell lines were considered sensitive and 11 were
insensitive. The resultingmodel fitted well (r2 = 0.36, χ 2 P = .015,Wald
test passed, AUC=0.86), and theROCcurve is presented inFigure 10B.
At this lower cutoff, the sensitivity and specificity are 88% and 86%,
respectively. It must be emphasized that with the low number of cell
lines tested and few biomarkers analyzed, these results should be viewed
as illustrative and not definitive.
It could be envisioned that such an approach may individualize
cancer chemotherapy with everolimus, if tumor biopsies could be
obtained before treatment and assessed for pAKT and p235-S6/total
S6 levels (using a suitable set of reference controls), and determine
the expression category for each marker. One difficulty is the relation
of IHC data (typically H -scores) with the continuous data provided
by quantitative Western blot or ELISA used preclinically or in clinical
trials. H-scores do not provide a unique number describing the marker
expression level, and it will have to be clarified if a very high level
marker expression by a few cells within a tumor is therapeutically equiv-
alent to a low-level expression bymost tumor cells; both scenarios could
give similarH-scores. Once the PK properties of everolimus in that pa-
tient are determined, comparing the marker expression level with the
achieved everolimus blood level will provide relevant decision-making
criteria regarding the continuance of everolimus therapy and the likeli-
hood of clinical success. However, this marker set cannot be used to
monitor response to treatment because insensitive cells show a decrease
in p235-S6 levels, which is not correlated to the eventual antitumor
effect preclinically (see earlier section). Furthermore, if rapalogs are used
in combination, these other agents can also induce significant effects on
pAKT and pS6 (see earlier section).
Nevertheless, the use of initial levels of pAKT and pS6 does seem
to have some predictive power for clinical outcome. For example, in
RCC, an initial high-level expression of pAKTand pS6 correlated with
outcome to treatment with the rapalog temsirolimus [48]. Also, in
Table 3. Univariate and Multiple Linear Regression Using Rank IC50 Values.
Regressor r ANOVA Results, P
Univariate linear regression
Total S6 0.48 .026
p235-240 S6 0.51 .017
p235/total S6 0.77 .001
pAkt 0.69 .006
Total AKT 0.45 .043
pAKT/total AKT 0.33 .14
Multivariate linear regression
11 parameters* 0.98 <.0001
p235/total S6 and pAKT 0.79 .0001
*Backward stepwise regression selected the following parameters to be used in multiple least
squares regression: total S6 levels, p235-S6, p240-S6, pEIF4, Rictor, Raptor, total AKT, pAKT,
and the ratios p235-S6/total S6, pAKT/AKT, and Rictor/Raptor.
Figure 8. Recursive partitioning of the sensitivity of the 21 tumor cell
lines to everolimus activity in vitro. H, high level expression; L, low
level expression.
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RCC, there was a positive and statistically significant correlation of
pS6 levels, and a trend for an association with a high-level pAKT ex-
pression, with temsirolimus response [49]. In breast cancer, PTEN,
pAKT, and pS6K1 levels were associated with rapamycin sensitivity,
and pS6K1-positive tumors were associated with a worse prognosis
compared with pS6K1-negative tumors [50]. Furthermore, pS6 expres-
sion has been linked to sensitivity to the rapalog AP23573 where a
high-level pS6 expression (≥20% of tumor cells staining) was associated
Figure 9. Segregation of 21 tumor cell lines according to levels (A) or categories (B, C) of p-AKT and the ratio of p235-S6/total S6. L,H, low
pAKT expression and high p235 S6/total S6 expression; H,H, high pAKT expression and high p235 S6/total S6 expression; H,L, high pAKT
expression and lowp235S6/total S6 expression; L,L, lowpAKTexpression and lowp235S6/total S6 expression. Sensitive (S): IC50<100 nM;
insensitive (IS): IC50 > 100 nM.
Figure 10. ROC curve of pAKT and p235-S6/total S6 levels as predictors of sensitivity of 21 tumor cell lines to everolimus. Nominal logistic
regression was performed using sensitivity to everolimus at the 100 nM (A) and 4 nM (B) cutoff limits and pAKT and p235 S6/total S6
expression categories (see legend to Figure 9) and the ROCs derived from the regression are presented.
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with a clinical response among metastatic sarcoma patients, whereas a
low expression (<10% of tumor cells) was not [51].
Whatever molecular approach is used, there persists several impor-
tant issues: 1) biopsies are not always readily obtained because of a) ac-
cess and b) consent; 2) a biopsy is only ever a small sample from a very
heterogeneous target tissue; and 3) in particular, for IHC, the samples
need to be carefully preserved because they may degrade. Consequently,
alternatives such as noninvasive imaging, which can sample the whole
tissue, are potentially very attractive.
Alternatives to Molecular Stratification
Given the complexity of the mTOR pathway, and the issues described
above, it may be that other generic nonmolecular approaches to deter-
mine tumor response before, or even soon after treatment, may also
prove beneficial. In this respect, one should consider the possibilities
of functional imaging using dynamic contrast-enhanced magnetic reso-
nance imaging (DCE-MRI) or ultrasound (US) and positron emission
tomography (PET). In principle, these methods can measure aspects
of tumor biology relevant to the downstream effects of everolimus:
DCE-MRI/US for antivascular/antiangiogenic effects and 18FDG-
and 18FLT-PET formeasuring effects on glycolysis and cell proliferation,
respectively. At present, preclinical data using these methods are scarce,
and there is even less in the clinic.
With respect to antivascular effects, DCE-US has shown that evero-
limus (5 mg/kg for 3 weeks) significantly decreased perfusion of
tumors growing s.c. in rats, and this paralleled growth inhibition
[52]. Similar reductions in tumor blood flow were observed using a
Doppler method in C57BL/6 mice bearing GL261 tumors [53]. In
contrast, DCE-MRI was unable to detect any significant changes in
tumor vessel permeability (K trans) or blood volume in murine B16/BL6
melanoma and rat breast BN472 tumors [9]. The absence of an effect
on K trans was consistent with the lack of effect on Evans Blue measure-
ment of permeability in the B16/BL6 model, and this suggests that,
although everolimus does have antiangiogenic activity, this is mani-
fested differently in comparison to VEGF-R or PI3K inhibitors [54].
Everolimus has been reported to rapidly reduce both FDG and FLT
uptake in xenograft models that are classified as sensitive but not in
the insensitive models [55]. Similar data were shown for rapamycin
in human tumor xenografts where reduced tracer uptake was linked
to decreased activity of hexokinase for FDG and thymidine kinase 1
for FLT [56]. Everolimus was shown to dose-dependently reduce
FDG uptake in a gastric xenograft model, with the effect showing a
plateau at 5 to 15 mg/kg daily, consistent with effects on pS6 in the
same model [57]. These effects also paralleled those on growth inhibi-
tion, and thus, this study emphasized the potential power of FDG-PET
to obtain an OBD for clinical application. In contrast, the only full
clinical report for the effect of rapalogs on imaging indicated that, al-
though rapamycin reduced FDG uptake in 17 of 34 patients, 46% of
these patients progressed, suggesting that the PETmethod was not of
value in predicting response to rapamycin at the dose and schedule used
in that study [58].
Lastly, it is possible that imaging could also be used for stratification,
in particular, if one considers the antivascular/antiangiogenic charac-
teristics of mTORi. For example, if the PI3K/AKT/mTOR is highly
activated in a particular tumor, then this should lead to an increased
expression of HIF-1 and, consequently, increased expression of VEGF
and platelet-derived growth factor and increased glucose transport and
glycolysis (Figure 1B). Thus, it may be that sensitive tumors have, at
baseline, higher rates of glucose uptake and/or vascularity; the latter
manifested as a higher vessel density or increased blood volume, perme-
ability, or flow. These characteristics are all detectable by the different
noninvasive imaging methods described, i.e., FDG-PET, DCE-MRI,
and also arterial spin labeling (ASL) for blood flow. Indeed, in RCC
clinical trials, the VEGF-R inhibitor sorafenib showed significantly in-
creased activity in tumors with a higher permeability (K trans) than in
those with a lower permeability [59]. Recently, a similar approach has
been followed in experimental RCC models where tumor blood flow
was measured by ASL at baseline and in response to sorafenib, which
showed increased sensitivity in tumors with higher blood flow [60].
Thus, where imaging methods have been set up to monitor early re-
sponse, retrospective analysis may indicate cutoffs in vascularity or gly-
colysis that can assign tumors into sensitive or insensitive groups,
perhaps eventually providing the opportunity for stratification on the
basis of noninvasive imaging.
Conclusions
Through a concentrated research effort acquiring a solid understand-
ing of the molecular targets and affected pathways of everolimus (both
in vitro and in vivo), along with a clear definition of more classic phar-
macological aspects (dose-response, PK/PD relationship, therapeutic
window, etc.), principles were obtained, which were used to formulate
clinically testable questions that guided initial clinical trials. This en-
deavor reduced the clinical efforts needed to decide on the optimal dose
for further testing, allowing a rapid progression from phase 1 trials to
successful phase 3 trials. This effort also demonstrates that the appro-
priate use of animal models, on the basis of a thorough knowledge of
the properties of the model and restricting the questions asked to those
that the model is capable of answering, does indeed provide a predictive
system from which to plan clinical trials.
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